Skip to content

IEMbase 0005: QDPR-related dihydropteridine reductase deficiency

Scope

Field Value
IEMbase ID 5
Nosology 21.1.05.01
Gene QDPR
External IDs OMIM:261630
Generated mapping MAPPED by alias_exact:dihydropteridine reductase deficiency
DisMech target kb/disorders/Tetrahydrobiopterin_Deficiency.yaml#DHPR Deficiency
Review date 2026-07-07

IEMbase phenotype signal

Characteristic clinical features include axial hypotonia, basal ganglia calcifications on CT, intellectual disability, and myoclonic seizures. Additional features include choreoathetosis, cortical/subcortical atrophy, drooling, abnormal EEG with generalized slowing or spike-wave discharges, hypopigmented hair, microcephaly, pneumonia, psychomotor delay, eczematous rash, tonic-clonic seizures, sudden death, and temperature instability.

The biochemical pattern includes increased phenylalanine, low CSF 5-HIAA and homovanillic acid, low DHPR activity in dried blood spots, BH4 loading response, increased biopterin and BH2, generally normal neopterin, and increased prolactin.

Treatments listed are sapropterin/BH4, phenylalanine-reduced diet, levodopa/carbidopa, 5-hydroxytryptophan, and folinic acid.

DisMech phenotype coverage

DisMech correctly maps this to the DHPR subtype of Tetrahydrobiopterin Deficiency. The local umbrella captures the major shared phenotype set: hyperphenylalaninemia, developmental delay, intellectual disability, hypotonia, dystonia/parkinsonism, oculogyric crisis, seizures, hyperprolactinemia, CSF neurotransmitter metabolites, pterin profiling, and the expected therapies including folinic acid.

Concordance and completeness

Judgement: correct mapping with moderate-to-high concordance.

IEMbase is richer for subtype-specific diagnostic detail. DisMech does not currently expose DHPR activity, BH2 elevation, neopterin-normal pattern, basal ganglia calcification, EEG abnormalities, or brain atrophy as explicit subtype-level findings.

Curation actions

  • Keep the mapping.
  • Consider DHPR-specific biochemical entries for dried-blood-spot DHPR activity, BH2 elevation, and pterin-pattern interpretation.
  • Consider basal ganglia calcification and EEG abnormalities if supported by accepted sources.